Picture of Vivos Therapeutics logo

VVOS — Vivos Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Vivos Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

* Vivos Therapeutics Inc  VVOS.OQ  reported a quarterly
adjusted
loss of $3.05​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of $-5.00.  The mean expectation of two analysts
for the quarter was for a loss of $1.90 per share. Wall Street
expected results to range from $-2.06 to $-1.75 per share.
    * Revenue fell 17.8% to $3.25 million from a year ago;
analysts
expected $3.41 million. 
    * Vivos Therapeutics Inc's reported EPS for the quarter was
a loss
of $3.05​.
    * The company reported a quarterly loss of $4.26 million.
    * Vivos Therapeutics Inc shares had fallen by 62.6% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 7.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for Vivos
Therapeutics Inc is $7.13 
This summary was machine generated from LSEG data March 28 at
09:37 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -1.90          -3.05          Missed
 Sep. 30 2023      -3.12          -1.62          Beat
 Jun. 30 2023      -3.62          -4.50          Missed
 Mar. 31 2023      -4.50          -1.75          Beat

Recent news on Vivos Therapeutics

See all news